IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.555
EU - Europa 3.926
AS - Asia 3.880
SA - Sud America 825
Continente sconosciuto - Info sul continente non disponibili 276
AF - Africa 262
OC - Oceania 9
Totale 20.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.317
SG - Singapore 1.341
RU - Federazione Russa 722
VN - Vietnam 708
CN - Cina 666
BR - Brasile 659
IT - Italia 646
UA - Ucraina 478
SE - Svezia 392
IE - Irlanda 389
DE - Germania 371
HK - Hong Kong 367
FR - Francia 210
TR - Turchia 203
FI - Finlandia 188
GB - Regno Unito 174
DK - Danimarca 158
CI - Costa d'Avorio 152
IN - India 141
CA - Canada 126
KR - Corea 104
BD - Bangladesh 91
AR - Argentina 63
NL - Olanda 44
JP - Giappone 42
ID - Indonesia 39
MX - Messico 39
PL - Polonia 37
ZA - Sudafrica 36
IQ - Iraq 30
CO - Colombia 25
MA - Marocco 24
EE - Estonia 23
EC - Ecuador 22
ES - Italia 22
PK - Pakistan 22
BE - Belgio 20
PH - Filippine 19
VE - Venezuela 16
UZ - Uzbekistan 13
HN - Honduras 12
EG - Egitto 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
MY - Malesia 9
TT - Trinidad e Tobago 9
AT - Austria 8
AZ - Azerbaigian 8
CL - Cile 8
CR - Costa Rica 8
DZ - Algeria 8
IL - Israele 8
LB - Libano 8
PE - Perù 8
SV - El Salvador 8
AU - Australia 7
BO - Bolivia 7
CZ - Repubblica Ceca 7
KE - Kenya 7
KZ - Kazakistan 7
NI - Nicaragua 7
CW - ???statistics.table.value.countryCode.CW??? 6
DO - Repubblica Dominicana 6
LT - Lituania 6
PS - Palestinian Territory 6
EU - Europa 5
GT - Guatemala 5
JM - Giamaica 5
JO - Giordania 5
NP - Nepal 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
BB - Barbados 4
BY - Bielorussia 4
CH - Svizzera 4
SY - Repubblica araba siriana 4
ET - Etiopia 3
GP - Guadalupe 3
GR - Grecia 3
PR - Porto Rico 3
TH - Thailandia 3
AO - Angola 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LU - Lussemburgo 2
MU - Mauritius 2
NG - Nigeria 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CY - Cipro 1
GA - Gabon 1
Totale 20.446
Salva come PNG Salva come JPEG
Città #
Ashburn 1.855
Singapore 896
Chandler 857
Fairfield 705
Des Moines 688
Dallas 557
Jacksonville 530
San Jose 471
Council Bluffs 406
Dublin 387
Wilmington 381
Hong Kong 362
Boardman 319
Woodbridge 306
New York 294
Seattle 274
Houston 262
Ho Chi Minh City 228
The Dalles 197
Cambridge 195
Beijing 168
Princeton 166
Hanoi 160
Lawrence 159
San Mateo 153
Abidjan 152
Los Angeles 144
Lauterbourg 140
Ann Arbor 126
Moscow 113
Centro 98
Munich 89
San Diego 79
Santa Clara 66
Helsinki 65
Milan 64
Chicago 62
Pune 59
Hefei 54
São Paulo 54
Orem 48
Columbus 47
Da Nang 47
Vancouver 45
London 44
Turku 43
Washington 41
Buffalo 40
Turin 40
Tokyo 37
Marche 33
Brooklyn 31
Haiphong 31
Warsaw 31
Phoenix 29
Atlanta 28
Frankfurt am Main 28
Guangzhou 27
Redmond 26
Miano 25
Rome 24
Chennai 22
Denver 22
Falls Church 22
Montreal 22
Shanghai 22
Ancona 20
Mexico City 20
Norwalk 20
Johannesburg 19
San Francisco 19
Wuhan 19
Brussels 17
Rio de Janeiro 17
Belo Horizonte 16
Manchester 16
Brasília 15
Poplar 15
Stockholm 15
Clovis 14
Jakarta 14
Jiaxing 14
Hải Dương 13
Newark 13
Tashkent 13
Amsterdam 12
Baghdad 12
Boston 12
Can Tho 12
Porto Alegre 12
Seoul 12
Ankara 11
Kilburn 11
Mumbai 11
Destin 10
Guarulhos 10
New Delhi 10
Quận Ba 10
Thái Nguyên 10
Curitiba 9
Totale 13.669
Salva come PNG Salva come JPEG
Nome #
Metabolic phenotype of bladder cancer 271
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 212
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 207
Designing novel immunocombinations in metastatic renal cell carcinoma 207
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 206
Predicting future cancer burden in the United States by artificial neural networks 204
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 201
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 193
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 192
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 190
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 185
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 180
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 176
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 176
Exploring the Spectrum of Kidney Ciliopathies 176
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 175
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 173
HER family receptor expression and prognosis in pancreatic cancer 173
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 173
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 171
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 168
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 168
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 167
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 167
An update on investigational therapies that target STAT3 for the treatment of cancer 167
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 166
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 165
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 165
Microbiome and cancers, with focus on genitourinary tumors 164
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 164
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 162
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 161
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 161
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 161
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 159
Metabolic Alterations in Renal and Prostate Cancer 158
High CTLA-4 expression correlates with poor prognosis in thymoma patients 158
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 156
Molecular characterization of testicular germ cell tumors using tissue microdissection 155
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 154
Bone targeting agents in patients with metastatic prostate cancer: State of the art 154
Trattamento del carcinoma del pancreas. Attualità e prospettive 153
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 150
Hyponatremia in cancer patients: Time for a new approach 149
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 149
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 148
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 147
Is There a Role for Immunotherapy in Prostate Cancer? 147
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 146
An overview of emerging immunotargets of genitourinary tumors 144
AR-V7 and prostate cancer: The watershed for treatment selection? 144
Pd-l1 inhibitors for the treatment of prostate cancer 144
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 140
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 139
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 139
Bladder cancer: molecular determinants of personalized therapy 139
Present and future of personalized medicine in adult genitourinary tumors 137
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 137
The identification of immunological biomarkers in kidney cancers 137
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 136
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 135
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 135
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 135
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 132
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 132
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 132
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 131
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 131
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 130
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 130
An update on immunotherapy in uro-oncology 130
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 130
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 129
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 128
Urinary catheters and biofilm formation 126
Emerging Immunotargets and Immunotherapies in Prostate Cancer 125
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 124
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 123
Exploring small extracellular vesicles for precision medicine in prostate cancer 122
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 121
Renal Cell Carcinoma: genomic landscape and clinical implications 121
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 120
Role of STAT3 pathway in genitourinary tumors 119
Epigenetic modulations and lineage plasticity in advanced prostate cancer 119
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 119
Pazopanib and sunitinib trigger autophagic and non autophagic death of bladder tumor cells. 117
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 117
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 117
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 117
Agent-Based Learning Model for the Obesity Paradox in RCC 117
Treating prostate cancer by antibody-drug conjugates 117
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 117
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 116
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 114
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 114
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 114
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 114
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 114
The route to personalized medicine in bladder cancer: where do we stand? 114
Totale 14.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.531
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.531
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022898 0 0 0 24 26 142 33 65 101 118 134 255
2022/20232.865 238 271 148 214 151 879 6 156 584 13 152 53
2023/20241.401 238 34 99 162 203 362 30 41 4 30 17 181
2024/20252.547 322 206 32 16 103 88 240 92 585 239 275 349
2025/20267.123 447 509 475 541 824 466 1.335 735 662 569 160 400
2026/20271.294 271 250 260 513 0 0 0 0 0 0 0 0
Totale 20.733